Articles by Michael Okonkwo
SpaceX Edges Up 0.5% as Louisiana Starbase's $100B Capex Plan Fuels IPO Speculation
SpaceX stock rose 0.45% to $141.50 as the company's $100B Louisiana Starbase commitment shifts focus to execution, with construction set for 2027 and first launch in 2029.
Wellchange Stock Soars 33% Despite 85% Discounted Share Sale
Wellchange shares surged 33% despite pricing a 50 million-share offering at an 85% discount, raising $7.5 million. The deal highlights investor speculation amid heavy dilution.
Exascale Labs Debuts on Nasdaq, Shares Jump 12% Despite Funding Gap
Exascale Labs (XLAB) rose 12% in its Nasdaq debut, but a $12M cash balance against a $300M pipeline signals a funding gap for AI infrastructure growth.
Pasqal Soars 55% in Nasdaq Debut After $2B Quantum Merger
Pasqal shares jumped 54.7% to $15.14 on Nasdaq debut after $2B merger, while rivals IonQ, Rigetti, D-Wave, and Quantum Computing declined.
Cre8 Enterprise Stock Soars 165% on Record IPO Workload
Cre8 Enterprise shares surged 165% after reporting record customer activity and a 482% jump in Hong Kong IPO submissions, adding $8.5 million in market value.
Generate Biomedicines Plunges 20% as Lock-Up Expiry Floods Market
Generate Biomedicines (GENB) shares fell 20% as a 103.14 million-share lock-up expired, quadrupling the tradable float and heightening supply worries.
Generate Biomedicines Surges 12% Ahead of Lockup Expiry
Generate Biomedicines (GENB) shares jumped 12.3% ahead of the expiration of a 103.14 million-share lockup, with trading volume nearly four times the average.
SpaceX Share Unlock Tests SPCX Liquidity Near IPO Price
SpaceX's 319 million-share unlock pressured SPCX near its $135 IPO price. Shares closed at $136.97, with analysts split on valuation.
Werewolf Therapeutics Stock Doubles on Ambros Merger; Legacy Holders Get 6.8%
Werewolf Therapeutics shares doubled after announcing a merger with Ambros Therapeutics. Existing shareholders will hold only 6.8% of the combined entity, with a $150 million PIPE funding the lead drug program.
SpaceX Shares Slide 5.6% as 319 Million Insider Shares Become Tradable
SpaceX shares dropped 5.6% as 319 million insider shares unlocked, wiping out $103 billion in market value. Trading volume was thin, and analysts remain split.
SpaceX Shares Slide 2.6% as 319 Million-Share Lockup Expiry Looms
SpaceX shares dropped 2.6% to $139.65 as a 319 million-share lockup expiry approaches, representing 4.4 times Wednesday's volume. The stock remains 3.4% above its IPO price.
CXMT's $586B Valuation Hinges on Tiny 6.7% Float
CXMT's $586B market cap is supported by only 6.7% tradable shares, amplifying volatility. The stock fell 2.77% to ¥57.55, but remains up 7.5% since Aug. 12.